Brachytherapy News and Research

RSS
Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.
New REACT medical trial for early diagnosis of lung cancer

New REACT medical trial for early diagnosis of lung cancer

Varian's Acuros XB dose calculation algorithm for radiotherapy receives FDA 510(k) clearance

Varian's Acuros XB dose calculation algorithm for radiotherapy receives FDA 510(k) clearance

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treatment

IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treatment

UMC of Göttingen purchases BSD-500 Hyperthermia System

UMC of Göttingen purchases BSD-500 Hyperthermia System

NeedleTech increases production area with new 73,000-square foot manufacturing facility

NeedleTech increases production area with new 73,000-square foot manufacturing facility

Robot-assisted brachytherapy for treating prostate cancer

Robot-assisted brachytherapy for treating prostate cancer

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

Humanitas Clinic treats first cancer patient using TrueBeam technology

Humanitas Clinic treats first cancer patient using TrueBeam technology

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Cs-131 brachytherapy seed implant can treat metastasized cancer

Cs-131 brachytherapy seed implant can treat metastasized cancer

Varian, IMRIS enter agreement to co-develop new MR-guided radiation therapy system for cancer

Varian, IMRIS enter agreement to co-develop new MR-guided radiation therapy system for cancer

IsoRay reports increase revenue for 2010 fiscal year

IsoRay reports increase revenue for 2010 fiscal year

Premier Purchasing Partners announces new agreements for radiation oncology portfolio

Premier Purchasing Partners announces new agreements for radiation oncology portfolio

Cianna Medical launches SAVI Sisters program to educate about breast cancer treatment options

Cianna Medical launches SAVI Sisters program to educate about breast cancer treatment options

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron to present innovative cancer treatment during ESTRO29

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.